In a historic move, the United Nations (UN) has voted to reclassify cannabis and cannabis resin, removing them from the list of the most harmful drugs under the 1961 Convention on Narcotic Drugs. This decision marks a significant shift in the global perception of cannabis, especially in its application within the medical field.
*Source: El País: https://elpais.com/sociedad/2020-12-02/la-onu-reconoce-oficialmente-las-propiedades-medicinales-del-cannabis.html
A long-awaited change
For years, the debate over the therapeutic properties of cannabis has been at the center of many scientific and political discussions. Despite restrictions and stigmatization, numerous studies have shown the multiple benefits of cannabis to treat various health conditions, from muscle pain and chronic diseases to improving sleep quality.
This UN recognition not only validates the therapeutic benefits of cannabis but also facilitates the research and development of new treatments based on this plant.
“According to the CIS, in Spain 84% of Spaniards are in favour of the legalisation of cannabis for therapeutic purposes.”
The 1961 Convention on Narcotic Drugs and the Reclassification
The Convention on Narcotic Drugs classifies narcotic drugs into four schedules, with Group IV being the most controlled and considered the most dangerous. The recent vote has moved cannabis to Group I, where substances with significant medical value are recognized.
This change opens new doors for scientific research and regulation of the therapeutic use of cannabis, ushering in a new era in alternative medicine.
Impact on Legalization and Research
With the reclassification of cannabis, an acceleration in the regulation of its medicinal use is expected, facilitating access to alternative treatments for patients worldwide. In addition, by leaving the group of the most controlled drugs, scientific research is encouraged, allowing a greater understanding of their therapeutic applications.
The situation in Spain
In Spain, where 84% of the population supports the legalisation of cannabis for therapeutic purposes, this UN change is a step forward towards the acceptance and regulation of medical cannabis. Although recreational use remains illegal, a clear distinction between CBD and THC is crucial to advancing legislation and responsible use.
CBD: The Non-Psychoactive Component
CBD, or cannabidiol, is a component of cannabis that does not produce psychoactive effects, thus differentiating itself from THC. In 2017, the WHO stated that CBD is not addictive or harmful to health, which has prompted its legalization and use in professional sports and the 2021 Olympics.
Studies have shown that CBD can have protective effects on the nervous system, as well as relieving seizures, pain, anxiety, and inflammation, expanding its range of therapeutic applications.
Towards Destigmatization and Regularization
This UN breakthrough is a crucial step towards destigmatising and regularising the use of cannabis and CBD, opening the way for a deeper understanding of their benefits. The expansion of CBD-rich products reflects the growing interest in and acceptance of these substances as viable treatment options.
Conclusion
The UN’s decision to recognize the therapeutic properties of cannabis represents an important milestone in the history of medical cannabis. By facilitating research and potentially regulating its therapeutic use, it opens up a world of possibilities for patients in search of natural alternatives for their well-being.
At Greenery, we remain committed to delivering high-quality, CBD-rich products, supporting the health and well-being of our customers. We invite you to explore our selection of bestsellers and discover for yourself the benefits of medical cannabis.
